Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Pembrolizumab in Advanced Solid Tumors
NCT03833427Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of selumetinib in solid tumor (7 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 28 months and 1 more. Started Mar 2019; status: terminated.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03833427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833427.